These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 9162395)

  • 21. [Thrombolytics and their use].
    Alessi MC; Juhan-Vague I
    Rev Prat; 1999 Oct; 49(15):1654-8. PubMed ID: 10581996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase fibrinolytic activity in rat aortic endothelial cells. Role of geranylgeranylation and Rho proteins.
    Essig M; Nguyen G; Prié D; Escoubet B; Sraer JD; Friedlander G
    Circ Res; 1998 Oct; 83(7):683-90. PubMed ID: 9758637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synergism of thrombolytic agents: investigational procedures and clinical potential.
    Collen D
    Circulation; 1988 Apr; 77(4):731-5. PubMed ID: 3127075
    [No Abstract]   [Full Text] [Related]  

  • 24. [Combined thrombolysis by pharmacokinetically different plasminogen activators].
    Maksimenko AV
    Bioorg Khim; 1998 May; 24(5):376-80. PubMed ID: 9661792
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [A hybrid molecule of pro-urokinase and a fibrin-specific, monoclonal antibody fragment is a more effective thrombolytic agent than pro-urokinase in vitro and in vivo].
    Bode C; Eberle T; Runge M; Haber E; Kübler W
    Verh Dtsch Ges Inn Med; 1990; 96():1-3. PubMed ID: 2128723
    [No Abstract]   [Full Text] [Related]  

  • 26. Molecular mechanisms of thrombolytic therapy.
    Lijnen HR; Collen D
    Haemostasis; 1986; 16 Suppl 3():3-15. PubMed ID: 2945766
    [No Abstract]   [Full Text] [Related]  

  • 27. Fibrinolytic agents and their effects on the haemostatic system.
    Kluft C
    Klin Wochenschr; 1988; 66 Suppl 12():50-4. PubMed ID: 2964542
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extraction of plasminogen activator in the rat's submaxillary gland.
    Lucas ON; Lucas GV
    Acta Physiol Pharmacol Ther Latinoam; 1995; 45(2):115-22. PubMed ID: 8580523
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Enhanced thrombolysis in plasma and in vivo by single-chain urokinase-type plasminogen activator (scuPA) conjugated to an antifibrin antibody.
    Bode C; Runge M; Eberle T; Freitag M; Kübler W; Haber E
    Trans Assoc Am Physicians; 1989; 102():7-12. PubMed ID: 2517856
    [No Abstract]   [Full Text] [Related]  

  • 30. The effect of chemical anti-inhibitors on fibrinolytic enzymes and inhibitors.
    Sidelmann J; Jespersen J; Kluft C; Gram J
    Clin Chim Acta; 1997 May; 261(1):43-56. PubMed ID: 9187504
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [New thrombolytic agents].
    Okada K
    Rinsho Byori; 1992 Mar; Suppl 92():115-30. PubMed ID: 1583770
    [No Abstract]   [Full Text] [Related]  

  • 32. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
    Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancement of fibrinolytic activity of vascular endothelial cells by chaetoglobosin A, crinipellin B, geodin and triticone B.
    Shinohara C; Chikanishi T; Nakashima S; Hashimoto A; Hamanaka A; Endo A; Hasumi K
    J Antibiot (Tokyo); 2000 Mar; 53(3):262-8. PubMed ID: 10819297
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158).
    Gurewich V; Pannell R; Broeze RJ; Mao J
    J Clin Invest; 1988 Dec; 82(6):1956-62. PubMed ID: 2974047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of desmoteplase-induced fibrinolytic activity in vitro.
    Hoffmann JJ; Kops O
    J Thromb Thrombolysis; 2005 Aug; 20(1):23-6. PubMed ID: 16133891
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of N-(1-naphthyl acetyl) piperazine hydrochloride (DQ-2777) on the activation of human plasminogen and the fibrinolysis.
    Sugiyama N; Saito T; Iwamoto M
    Thromb Res; 1988 Mar; 49(6):629-34. PubMed ID: 2968681
    [No Abstract]   [Full Text] [Related]  

  • 38. Fibrinolytic agents.
    Schmitz-Huebner U; van de Loo J
    Clin Haematol; 1981 Jun; 10(2):481-96. PubMed ID: 7032785
    [No Abstract]   [Full Text] [Related]  

  • 39. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
    Collen D
    Prog Hemost Thromb; 1986; 8():1-18. PubMed ID: 3104986
    [No Abstract]   [Full Text] [Related]  

  • 40. Development of novel thrombolytic agents.
    Collen D; De Bono DP; Lijnen HR; Pannekoek H
    J Intern Med; 1994 Oct; 236(4):433-7. PubMed ID: 7931045
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.